We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+9.38%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$5.45B
AUM Growth
+$30.2M
Cap. Flow
+$53.1M
Cap. Flow %
0.97%
Top 10 Hldgs %
47.61%
Holding
95
New
15
Increased
22
Reduced
33
Closed
14

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$199M
2
OSH
Oak Street Health, Inc.
OSH
+$119M
3
KYMR icon
Kymera Therapeutics
KYMR
+$83.4M
4
ANNX icon
Annexon
ANNX
+$80.8M
5
KLRS
Kalaris Therapeutics
KLRS
+$69.3M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$162M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$157M
3
BNTX icon
BioNTech
BNTX
+$132M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$64.2M
5
CYRX icon
CryoPort
CYRX
+$55M

Sector Composition

Rank Sector Weight
1 Healthcare 99.5%
2 Financials 0.5%
3 Technology 0%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$297M
$505M 9.27%
12,629,737
– –
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$326M 5.98%
23,075,807
-1,868,888
-7% -$27.2M
IMMU
3
DELISTED
Immunomedics Inc
IMMU
$275M 5.05%
3,234,934
-254,966
-7% -$12.9M
ARGX icon
4
argenx
ARGX
$64.6B
$259M 4.76%
988,468
-46,400
-4% -$11.2M
IGMS
5
DELISTED
IGM Biosciences
IGMS
$253M 4.64%
3,425,455
+281,455
+9% +$16.7M
DCPH
6
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$245M 4.5%
4,774,918
-204,023
-4% -$9.99M
ADCT icon
7
ADC Therapeutics
ADCT
$174M
$210M 3.85%
6,353,094
+827,224
+15% +$35.8M
ALLK
8
DELISTED
Allakos
ALLK
$198M 3.63%
2,425,560
-193,520
-7% -$15.7M
GILD icon
9
Gilead Sciences
GILD
$187B
$181M 3.33%
+2,869,962
New +$199M
OSH
10
DELISTED
Oak Street Health, Inc.
OSH
$142M 2.6%
+2,652,411
New +$119M
ANNX icon
11
Annexon
ANNX
$923M
$104M 1.91%
+3,442,122
New +$80.8M
EPZM
12
DELISTED
Epizyme, Inc
EPZM
$99.2M 1.82%
8,311,633
-173,972
-2% -$2.33M
ONEM
13
DELISTED
1Life Healthcare
ONEM
$94.9M 1.74%
3,344,694
+334,010
+11% +$10.5M
BIIB icon
14
Biogen
BIIB
$32.6B
$92.9M 1.71%
327,447
+165,147
+102% +$46.1M
NRIX icon
15
Nurix Therapeutics
NRIX
$2.71B
$90.5M 1.66%
+2,593,570
New +$65.4M
ATRA icon
16
Atara Biotherapeutics
ATRA
$98M
$89.9M 1.65%
277,555
+3,820
+1% +$1.3M
KYMR icon
17
Kymera Therapeutics
KYMR
$9.76B
$88.3M 1.62%
+2,732,660
New +$83.4M
SNY icon
18
Sanofi
SNY
$106B
$87.4M 1.61%
1,743,048
+517,548
+42% +$26.6M
BNTX icon
19
BioNTech
BNTX
$26.1B
$85.5M 1.57%
1,235,645
-1,833,519
-60% -$132M
STOK icon
20
Stoke Therapeutics
STOK
$1.92B
$85.4M 1.57%
2,549,506
+47,200
+2% +$1.35M
BEAM icon
21
Beam Therapeutics
BEAM
$3.06B
$81.9M 1.5%
3,327,262
-29,696
-0.9% -$737K
ZNTL icon
22
Zentalis Pharmaceuticals
ZNTL
$378M
$79.5M 1.46%
2,432,408
+771,203
+46% +$27M
PLRX icon
23
Pliant Therapeutics
PLRX
$71.8M
$76.8M 1.41%
3,391,757
-18,900
-0.6% -$472K
REPL icon
24
Replimune Group
REPL
$1.42B
$76.7M 1.41%
3,330,999
+226,806
+7% +$5.17M
RPTX
25
DELISTED
Repare Therapeutics
RPTX
$74M 1.36%
2,404,974
+18,800
+0.8% +$498K
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2020 Portfolio in Review

As of Q3 2020, Redmile Group held 95 positions worth $5.45B, up 0.56% from $5.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group's Q3 2020 filing shows 15 new, 22 increased, 33 reduced and 14 closed positions. Its largest new stake was Gilead Sciences: 2,869,962 shares worth $181M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $162M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials and Technology.

  • Redmile Group's largest Q3 2020 buy was Gilead Sciences: 2,869,962 shares worth $181M.
  • Redmile Group added most to Akero Therapeutics in Q3 2020, an estimated $67.9M increase.
  • Redmile Group's biggest Q3 2020 reduction was BioNTech, cutting an estimated $132M.
  • Redmile Group fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $162M.
  • Redmile Group's ten largest holdings make up 48% of its $5.45B portfolio in Q3 2020.
  • Redmile Group opened 15 new positions and closed 14 in Q3 2020.
  • Redmile Group's portfolio value rose 0.56% quarter-over-quarter to $5.45B.

Based on Redmile Group's 13F filing for Q3 2020, filed 16 Nov 2020.